CTKB
NASDAQCytek Biosciences Inc.
News25/Ratings12
Price$4.50-1.01 (-18.31%)
2026-01-212026-04-24
News · 26 weeks40-80%
2025-10-262026-04-19
Mix2190d
- Insider11(52%)
- Other4(19%)
- Earnings3(14%)
- SEC Filings3(14%)
Latest news
25 items- PRCytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation
- SECSEC Form SCHEDULE 13G filed by Cytek Biosciences Inc.SCHEDULE 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming gifted 1,176,000 shares, decreasing direct ownership by 19% to 4,915,933 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Chin Richard converted options into 6,107 shares, increasing direct ownership by 60% to 16,285 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF LEGAL OFFICER Barnett Valerie converted options into 29,722 shares and covered exercise/tax liability with 11,748 shares, increasing direct ownership by 15% to 134,436 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 9,828 shares and covered exercise/tax liability with 3,043 shares, increasing direct ownership by 23% to 35,687 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERPRESIDENT AND CEO Jiang Wenbin converted options into 83,844 shares and covered exercise/tax liability with 20,988 shares, increasing direct ownership by 1% to 5,422,683 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERChief Financial Officer Mccombe William D. converted options into 23,721 shares and covered exercise/tax liability with 9,748 shares, increasing direct ownership by 17% to 94,687 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming converted options into 25,400 shares and covered exercise/tax liability with 7,731 shares, increasing direct ownership by 0.29% to 6,091,933 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Holder Michael converted options into 2,908 shares, increasing direct ownership by 24% to 15,267 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRCytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional ImpactFREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) is marking a major milestone in its Asia-Pacific (APAC) expansion. Serving as a strategic hub supporting customers across APAC and worldwide, the Singapore facility has contributed to Cytek's growth over the past 12 months, significantly enhancing Cytek's manufacturing capacity, regional service and training capabilities, and reinforcing global supply chain resilience while helping mitigate geopolitical and trade-related risks. As life sciences research continues to expand worldwide, Cytek's Singapore oper
- SECSEC Form S-8 filed by Cytek Biosciences Inc.S-8 - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECSEC Form 10-K filed by Cytek Biosciences Inc.10-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECCytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 OutlookFREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of
- INSIDERPRESIDENT AND CEO Jiang Wenbin covered exercise/tax liability with 1,339 shares and converted options into 4,514 shares, increasing direct ownership by 0.06% to 5,359,827 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming covered exercise/tax liability with 395 shares and converted options into 1,332 shares, increasing direct ownership by 0.02% to 6,074,264 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF LEGAL OFFICER Barnett Valerie converted options into 1,346 shares and covered exercise/tax liability with 525 shares, increasing direct ownership by 0.71% to 116,462 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRCytek Biosciences to participate at the TD Cowen 46th Annual Health Care ConferenceFREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Cytek management is scheduled to participate in a hybrid presentation and fireside chat on Wednesday, March 4th at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing
- PRCytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the n
- SECCytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue ResultsFREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025. "Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation o
- ANALYSTMorgan Stanley resumed coverage on Cytek Biosciences with a new price targetMorgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming converted options into 21,031 shares and covered exercise/tax liability with 5,123 shares, increasing direct ownership by 0.26% to 6,073,327 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)